Cell TherapySuccessfully funded
Cell Therapy Limited has developed a breakthrough stem cell medicine, Heartcel, which regenerates heart muscle damaged as a result of heart attack or heart failure. One of the company’s founders is Prof. Sir Martin Evans, winner of the Nobel Prize for Medicine and Physiology in 2007 for his pioneering work in discovering stem cells. Heartcel is scheduled to launch in 2016 in the $50bn global heart failure market that affects 20 mn worldwide.
Founder: Professor Sir Martin Evans & Ajan Reginald
CTL was co-founded by Sir Martin Evans, the Nobel prize-winning scientist and Ajan Reginald Ex-Global Head of Emerging Technologies at Roche Pharma.
- Location: Llanedeyrn, Cardiff
- Target: £250,000 (0.39% equity)
- Share Type: A (£50,000), B
- Tax Relief: EIS
- Days Left: 0
- Payments: UK Only
- No Updates...
Join today to own a stake and share in the future success of ambitious British businesses you believe in.
- Sign up in just one minute
- Invest from just £10
- No money taken until pitch closes
Why invest in British businesses?
Potential of healthy returns
Investing in early-stage businesses, although risky, can also be very lucrative if you do your due diligence and spread your investment and risk across multiple businesses.
Generous tax reliefs
You may benefit from generous tax relief of up to 50 per cent where EIS or SEIS is eligible.
Support businesses you believe in
Make a difference and share in the success of British businesses that you believe in. Help them grow, create jobs and make an economic impact.
Ongoing Investor communications
Keep up-to-date with the progress of the businesses you back through our dedicated investor relations portal.
How does it work?
It only takes a minute to join and then you'll be able to see the full pitch. If you choose to invest we won't take your money until the pitch closes and you can cancel your investment at any time.
Invest alongside professional investors
Invest alongside Europe's leading venture capital firms, seasoned professional investors and the UK Government.
Choose between early-stage and well-known brands
Eden Project, River Cottage, JustPark, easyProperty and Sugru are just a few of the well-known British companies who have raised more than £100m from our 200,000+ investors.
Vetted by Crowdcube
Our legal, financial and investments team check the pitches on Crowdcube to ensure every one is fair, clear and not misleading.
Investing in start-ups and early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Crowdcube is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. You will only be able to invest via Crowdcube once you are registered as sufficiently sophisticated.
This page is approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority. Pitches for investment are not offers to the public and investments can only be made by members of crowdcube.com on the basis of information provided in the pitches by the companies concerned. Crowdcube takes no responsibility for this information or for any recommendations or opinions made by the companies.